Cohort Study to Determine the Impact of <i>CYP3A5</i> Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients
Our findings highlight the impact of CYP3A5 expresser status on the time needed and dosing requirements to attain tacrolimus therapeutic concentrations in heart transplant recipients, suggesting CYP3A5-guided dosing strategies may improve rapid attainment of therapeutic tacrolimus concentrations.
Authors
- Tyler Shugg (ORCID: https://orcid.org/0000-0002-5784-3565)
- E. Tillman
- Roopa A. Rao (ORCID: https://orcid.org/0000-0002-1750-389X)
- Michael T. Eadon (ORCID: https://orcid.org/0000-0003-3066-2876)
- L. Schenkelberg
- James C. Coons (ORCID: https://orcid.org/0000-0002-7193-3751)
- Yanting Wu
Institutions
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1002/phar.70116
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Indiana University Health
- School of Medicine, Indiana University